These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 11821468

  • 1. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.
    Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM.
    J Clin Oncol; 2002 Feb 01; 20(3):833-41. PubMed ID: 11821468
    [Abstract] [Full Text] [Related]

  • 2. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
    Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, Slawin KM.
    J Clin Oncol; 2001 Jun 01; 19(11):2856-64. PubMed ID: 11387358
    [Abstract] [Full Text] [Related]

  • 3. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
    Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, Diamandis EP.
    Urology; 2001 Mar 01; 57(3):471-5. PubMed ID: 11248622
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.
    Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM.
    Urology; 2001 Dec 01; 58(6):1008-15. PubMed ID: 11744478
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
    Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L.
    Eur Urol; 2005 May 01; 47(5):695-702. PubMed ID: 15826765
    [Abstract] [Full Text] [Related]

  • 11. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F.
    Urol Int; 2004 May 01; 72(1):62-5. PubMed ID: 14730168
    [Abstract] [Full Text] [Related]

  • 12. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
    Hong SK, Han BK, Jeong JS, Jeong SJ, Moon KH, Byun SS, Lee SE.
    Asian J Androl; 2008 Mar 01; 10(2):207-13. PubMed ID: 18097534
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples.
    Ismail HA, Pollak M, Behlouli H, Tanguay S, Bégin LR, Aprikian AG.
    BJU Int; 2003 Nov 01; 92(7):699-702. PubMed ID: 14616449
    [Abstract] [Full Text] [Related]

  • 15. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
    Correa LL, Neto LV, Lima GA, Gabrich R, Miranda LC, Gadelha MR.
    Int Braz J Urol; 2015 Nov 01; 41(1):110-5. PubMed ID: 25928516
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.
    Bubley GJ, Balk SP, Regan MM, Duggan S, Morrissey ME, Dewolf WC, Salgami E, Mantzoros C.
    J Urol; 2002 Nov 01; 168(5):2249-52. PubMed ID: 12394769
    [Abstract] [Full Text] [Related]

  • 18. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y, Sakai H, Hayashi T, Kanetake H.
    Prostate; 2003 Feb 01; 54(2):125-32. PubMed ID: 12497585
    [Abstract] [Full Text] [Related]

  • 19. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
    Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH, Roobol MJ, Pols HA, Lamberts SW, Schröder FH.
    J Clin Endocrinol Metab; 2004 Sep 01; 89(9):4391-6. PubMed ID: 15356036
    [Abstract] [Full Text] [Related]

  • 20. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM, Slawin KM.
    Cancer Res; 2002 Oct 15; 62(20):5974-9. PubMed ID: 12384565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.